Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 2210.

https://doi.org/10.1182/blood-2019-122272

Published: 2019

Journal Articles

Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelated Donors

Lauren M. Bohannon, BS, Kristin M. Page, MD, Yi Ren, MS, Sin-Ho Jung, PhD, Vinay K. Giri, BS, Meagan V. Lew, BS, Matthew Kelly, MD, Taewoong Choi, MD, Cristina Gasparetto, MD, Gwynn D. Long, MD, Richard D. Lopez, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD, Nelson J. Chao, MD, Mitchell E. Horwitz, MD, Anthony D. Sung, MD

Blood (2019) 134 (Supplement_1): 4613.

https://doi.org/10.1182/blood-2019-126906

Published: 2019

Journal Articles

Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality

Ko Ko Ko Maung, MD, Mohammad Chaudhry, MD, Yi Ren, MS, Sin-Ho Jung, PhD, Kristi M. Romero, BS, Kelly Corbet, BS, Nelson J. Chao, MD, Taewoong Choi, MD, Anna Mae Diehl, MD, Louis F. Diehl, MD, Cristina Gasparetto, MD, Mitchell E. Horwitz, MD, Gwynn D. Long, MD, Richard D. Lopez, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD, Keith Sullivan, MD, Mustafa R. Bashir, MD, Anthony D. Sung, MD

Blood (2019) 134 (Supplement_1): 5731.

https://doi.org/10.1182/blood-2019-121830

Published: 2019

Journal Articles

Financial Incentives to Increase Stool Collection Rates for Microbiome Studies in Adult Bone Marrow Transplant Patients

Jillian C. Thompson, MS, Yi Ren, MS, Kristi M. Romero, BS, Meagan V. Lew, BS, Amy T. Bush, BS, Julia A. Messina, MD, Sin-Ho Jung, PhD, Julie M. Miller, PhD, Zachary Zenko, PhD, Robert R. Jenq, MD, Jonathan U. Peled, MD, Marcel R.M. van den Brink, MD PhD, Nelson J. Chao, MD, Anthony D. Sung, MD

Blood (2019) 134 (Supplement_1): 5775.

https://doi.org/10.1182/blood-2019-128702

Published: 2019

Journal Articles

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

David J. Straus, Sin-Ho Jung, Brandelyn Pitcher, Lale Kostakoglu, John C. Grecula, Eric D. Hsi, Heiko Schöder, Leslie L. Popplewell, Julie E. Chang, Craig H. Moskowitz, Nina Wagner-Johnston, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl, Bruce D. Cheson, Nancy L. Bartlett

Blood (2018) 132 (10): 1013–1021.

https://doi.org/10.1182/blood-2018-01-827246

Published: 2018

Includes: Supplemental data

Journal Articles

Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)

Kristie A. Blum, MD, Sin-Ho Jung, PhD, Ian Barak, MS, Eric D. Hsi, MD, Nina D. Wagner-Johnston, MD, Beth Christian, MD, Jim Atkins, Bruce D. Cheson, MD, John P. Leonard, MD, Nancy L. Bartlett, MD

Blood (2017) 130 (Supplement 1): 485.

https://doi.org/10.1182/blood.V130.Suppl_1.485.485

Published: 2017

Journal Articles

Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611)

Michael Tallarico, MD, Jared Foster, PhD, Drew Seisler, PhD, Jacqueline Lafky, PhD, Arti Hurria, Aminah Jatoi, MD, Harvey Jay Cohen, MD, Hyman Muss, MD, Nancy L Bartlett, MD, Bruce Cheson, MD, Sin-Ho Jung, PhD, John C. Byrd, MD, John P. Leonard, MD, Chadi Nabhan, MD MBA, FACP

Blood (2016) 128 (22): 536.

https://doi.org/10.1182/blood.V128.22.536.536

Published: 2016

Journal Articles

Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance)

Frederick Lansigan, MD, Ian Barak, MS, Brandelyn Nicole Pitcher, MS, Sin-Ho Jung, PhD, Bruce Cheson, MD, Myron S. Czuczman, MD, Barbara W. Grant, MD, Peter Martin, MD, Eric D. Hsi, MD, Heiko Schoder, MD, Scott E. Smith, MD PhD, Nancy L Bartlett, MD, John P. Leonard, MD, Kristie Blum, MD

Blood (2016) 128 (22): 2953.

https://doi.org/10.1182/blood.V128.22.2953.2953

Published: 2016

Journal Articles

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Chaitra S. Ujjani, Sin-Ho Jung, Brandelyn Pitcher, Peter Martin, Steven I. Park, Kristie A. Blum, Sonali M. Smith, Myron Czuczman, Matthew S. Davids, Ellis Levine, Lionel D. Lewis, Scott E. Smith, Nancy L. Bartlett, John P. Leonard, Bruce D. Cheson

Blood (2016) 128 (21): 2510–2516.

https://doi.org/10.1182/blood-2016-06-718106

Published: 2016

Journal Articles

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Cara A. Rosenbaum, MD, Brandelyn Pitcher, MS, Nancy L Bartlett, MD, Sonali M. Smith, MD, Jane Jijun Liu, MD, Eric D. Hsi, MD, Sin-Ho Jung, PhD, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 2741.

https://doi.org/10.1182/blood.V126.23.2741.2741

Published: 2015

Journal Articles

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

David J. Straus, MD, Brandelyn Pitcher, MS, Lale Kostakoglu, MD MPH, John C Grecula, MD, Eric D. Hsi, MD, Heiko Schoder, MD, Sin-Ho Jung, PhD, Leslie L. Popplewell, MD, Julie E Chang, MD, Craig H Moskowitz, MD, Nina Wagner-Johnson, MD, John P. Leonard, MD, Jonathan W. Friedberg, MD MMSc, Brad S Kahl, MD, Bruce D. Cheson, MD, Nancy L. Bartlett, MD

Blood (2015) 126 (23): 578.

https://doi.org/10.1182/blood.V126.23.578.578

Published: 2015

Journal Articles

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Lawrence D. Kaplan, MD, Sin-Ho Jung, PhD, Wendy Stock, MD, Nancy L. Bartlett, MD, Brandelyn Pitcher, MS, John C. Byrd, MD, Kristie A. Blum, MD, Ann S. LaCasce, MD, Noreen Fulton, Eric D. Hsi, MD, David D Hurd, MD, Myron Czuczman, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 337.

https://doi.org/10.1182/blood.V126.23.337.337

Published: 2015

Journal Articles

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Chaitra S. Ujjani, MD, Sin-Ho Jung, PhD, Brandelyn Pitcher, MS, Peter Martin, MD, Steven I. Park, MD, Kristie A. Blum, MD, Sonali M. Smith, MD, Myron S. Czuczman, MD, Matthew S. Davids, MD, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 471.

https://doi.org/10.1182/blood.V126.23.471.471

Published: 2015

Journal Articles

Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202

Sonali M. Smith, MD, Brandelyn Pitcher, MS, Sin-Ho Jung, PhD, Nancy L. Bartlett, MD, Nina Wagner-Johnston, MD, Steven I. Park, MD, Kristy L. Richards, MDPhD, Amanda F. Cashen, MD, Bruce D. Cheson, MD, John P. Leonard, MD

Blood (2014) 124 (21): 3091.

https://doi.org/10.1182/blood.V124.21.3091.3091

Published: 2014

Journal Articles

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Noreen Fulton, B.S., Jeffrey Johnson, M.S., Lawrence D. Kaplan, M.D., Greg Koval, B.S., Greg Malnassy, B.S., Sin-Ho Jung, Ph.D., Steve Devine, M.D., Thomas C. Shea, M.D., John P. Leonard, M.D., Bruce D. Cheson, M.D., Wendy Stock, M.D.

Blood (2013) 122 (21): 3002.

https://doi.org/10.1182/blood.V122.21.3002.3002

Published: 2013

Journal Articles

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Vicki A. Morrison, MD, Sin-Ho Jung, PhD, Jeffrey Johnson, MS, Ann LaCasce, MD, Kristie A. Blum, MD, Nancy L. Bartlett, MD, Bruce D. Cheson, MD

Blood (2012) 120 (21): 3696.

https://doi.org/10.1182/blood.V120.21.3696.3696

Published: 2012

Journal Articles

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

James L. Rubenstein, M.D., Ph.D., Eric D. Hsi, MD, Jeffrey L. Johnson, Sin-Ho Jung, Barbara Grant, MD, Bruce D. Cheson, MD, Lawrence D. Kaplan, MD

Blood (2012) 120 (21): 301.

https://doi.org/10.1182/blood.V120.21.301.301

Published: 2012

Journal Articles

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Lale Kostakoglu, MD, MPH, Heiko Schoder, MD, Nathan Hall, MD, PhD, David J. Straus, MD, Jeffrey L Johnson, PhD, Lawrence Schwartz, MD, Ann LaCasce, MD, Sin-Ho Jung, PhD, Nancy L. Bartlett, MD, George P. Canellos, MD, Bruce D. Cheson, MD

Blood (2011) 118 (21): 3644.

https://doi.org/10.1182/blood.V118.21.3644.3644

Published: 2011

Journal Articles

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

David J. Straus, Jeffrey L. Johnson, Ann S. LaCasce, Nancy L. Bartlett, Lale Kostakoglu, Eric D. Hsi, Heiko Schöder, Nathan C. Hall, Sin-Ho Jung, George P. Canellos, Lawrence H. Schwartz, Ronald W. Takvorian, Malik E. Juweid, Bruce D. Cheson, for Cancer and Leukemia Group B

Blood (2011) 117 (20): 5314–5320.

https://doi.org/10.1182/blood-2010-10-314260

Published: 2011

Journal Articles

Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202

James L. Rubenstein, M.D., Ph.D., Jeffrey L. Johnson, Sin-Ho Jung, Bruce D. Cheson, MD, Lawrence D. Kaplan, MD

Blood (2010) 116 (21): 763.

https://doi.org/10.1182/blood.V116.21.763.763

Published: 2010

NARROW

Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation

Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelated Donors

Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality

Financial Incentives to Increase Stool Collection Rates for Microbiome Studies in Adult Bone Marrow Transplant Patients

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)

Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611)

Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance)

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only